Financial Snapshot

Revenue
$850.0K
TTM
Gross Margin
Net Earnings
-$47.76M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
3183.85%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$138.4M
Q3 2024
Cash
Q3 2024
P/E
-4.350
Nov 29, 2024 EST
Free Cash Flow
-$34.21M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $12.24M $11.66M $10.93M $12.91M $11.60M $11.22M
YoY Change 5.02% 6.69% -15.35% 11.25% 3.44%
% of Gross Profit
Research & Development $38.12M $30.00M $20.34M $14.90M $22.45M $27.10M
YoY Change 27.08% 47.5% 36.45% -33.61% -17.15%
% of Gross Profit
Depreciation & Amortization $700.0K $800.0K $600.0K $2.400M $2.100M $1.921M
YoY Change -12.5% 33.33% -75.0% 14.29% 9.32%
% of Gross Profit
Operating Expenses $50.36M $41.66M $81.88M $27.81M $22.45M $38.31M
YoY Change 20.91% -49.13% 194.41% 23.89% -41.4%
Operating Profit -$50.36M -$41.66M -$81.88M -$27.81M -$34.05M
YoY Change 20.91% -49.13% 194.41% -18.32%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $7.869M $0.00 $370.0K $908.0K $1.228M $129.0K
YoY Change -100.0% -59.25% -26.06% 851.94%
% of Operating Profit
Other Income/Expense, Net $7.869M $2.430M -$299.0K -$1.656M -$601.0K
YoY Change 223.83% -912.71% -81.94% 175.54%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$42.49M -$39.23M -$82.18M -$29.47M -$34.65M -$38.18M
YoY Change 8.33% -52.27% 178.88% -14.96% -9.24%
Income Tax $0.00 $0.00 $0.00 $32.00K $91.00K $103.0K
% Of Pretax Income
Net Earnings -$42.49M -$39.23M -$82.18M -$29.50M -$34.74M -$38.29M
YoY Change 8.33% -52.27% 178.58% -15.09% -9.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33 -$0.37 -$1.31
Diluted Earnings Per Share -$0.33 -$0.37 -$1.307M -$958.5K -$666.2K -$734.1K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $152.5M $186.6M $144.5M $47.08M $25.30M $57.51M
YoY Change -18.3% 29.13% 206.98% 86.05% -56.0%
Cash & Equivalents $24.23M $34.95M $144.5M $47.08M $25.30M $57.51M
Short-Term Investments $128.2M $151.7M
Other Short-Term Assets $1.420M $8.182M $2.591M $3.126M $935.0K $1.370M
YoY Change -82.64% 215.79% -17.11% 234.33% -31.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $153.9M $194.8M $147.1M $50.20M $26.24M $58.88M
YoY Change -21.0% 32.42% 193.03% 91.33% -55.44%
Property, Plant & Equipment $2.674M $4.534M $6.332M $1.126M $3.751M $5.367M
YoY Change -41.02% -28.4% 462.34% -69.98% -30.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $320.0K $320.0K $583.0K $392.0K $377.0K
YoY Change 0.0% 0.0% -45.11% 48.72% 3.98%
Total Long-Term Assets $2.994M $4.854M $6.652M $1.709M $4.143M $5.744M
YoY Change -38.32% -27.03% 289.23% -58.75% -27.87%
Total Assets $156.9M $199.6M $153.8M $51.91M $30.38M $64.63M
YoY Change
Accounts Payable $4.090M $3.382M $867.0K $1.061M $629.0K $1.730M
YoY Change 20.93% 290.08% -18.28% 68.68% -63.64%
Accrued Expenses $3.711M $12.79M $9.764M $1.571M $3.122M $2.657M
YoY Change -70.98% 30.96% 521.51% -49.68% 17.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $7.467M $5.576M $3.688M
YoY Change -100.0% 33.91% 51.19%
Total Short-Term Liabilities $7.801M $16.17M $10.63M $10.10M $9.821M $8.465M
YoY Change -51.75% 52.09% 5.27% 2.83% 16.02%
Long-Term Debt $0.00 $0.00 $0.00 $1.867M $9.293M $11.06M
YoY Change -100.0% -79.91% -16.01%
Other Long-Term Liabilities $536.0K $1.838M $3.048M
YoY Change -70.84% -39.7%
Total Long-Term Liabilities $536.0K $1.838M $3.048M $1.867M $9.293M $11.06M
YoY Change -70.84% -39.7% 63.26% -79.91% -16.01%
Total Liabilities $8.337M $18.01M $13.68M $11.97M $19.11M $19.53M
YoY Change -53.7% 31.64% 14.32% -37.4% -2.13%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 127.0M 105.2M 62.87M
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $207.76 Million

About Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.

Industry: Biological Products, (No Diagnostic Substances) Peers: Actinium Pharmaceuticals, Inc. FENNEC PHARMACEUTICALS INC. Lineage Cell Therapeutics, Inc. Clene Inc. Gritstone bio, Inc. VBI Vaccines Inc/BC MACROGENICS INC Viking Therapeutics, Inc. XOMA Royalty Corp